What does the cxo plate mean?

CXO is the general name of pharmaceutical outsourcing track. The so-called pharmaceutical outsourcing refers to all kinds of outsourcing services provided by CXO enterprises for pharmaceutical enterprises from research and development of new drugs to production, which can reduce costs and increase efficiency.

According to the different outsourcing links, CXO track can be subdivided into several branches, mainly including CRO and CDMO.

CRO refers to contract research organization, which mainly focuses on clinical research outsourcing, including the process of screening potential patented compounds until clinical trials are completed. On the other hand, CDMO focuses on production services, providing services such as new drug process development, API production, intermediate manufacturing, preparation production and packaging.

Straight flush related plate (code 885927) is called CRO concept, but accurately speaking, this industry should be collectively referred to as CXO.

2. What is the core company of 2.CXO?

According to the different links of providing outsourcing services, CXO companies can be mainly divided into three categories: whole process, CRO and CDMO.

(1) WuXi PharmaTech and Kang Longhua Cheng, core CXO companies that provide outsourcing services for R&D new drugs from production to sales, are industry leaders, covering all stages of new drug research and development.

(2) CRO core companies focusing on outsourcing-Tiger Medicine, Zhao Yanxin Medicine, Medici and Chengdu Pioneer. Among them, Tiger Pharmaceutical provides all stages of research outsourcing, while Medici, Zhao Yan New Drugs and Chengdu Pioneer mainly provide research and development services for new drugs before they enter clinical trials.

(3) The core CDMO companies that focus on production outsourcing-Gloria, Boteng, Jiuzhou Pharmaceutical, Shi Yao Science and Technology, Haoyuan Medicine (among them, Shi Yao Science and Technology and Haoyuan Medicine provide characteristic molecular blocks that can be applied to all stages of R&D to production, but from the perspective of revenue ratio, Shi Yao Science and Technology and Haoyuan Medicine are currently focusing on CDMO and do not fall into the first category).

3. What are the reasons for the continuous rise of 3.CXO industry?

The continuous rise of CXO industry is due to the high certainty of track prosperity. The influence of three main factors on the high prosperity of pharmaceutical outsourcing industry will continue: the acceleration of new drug application (the expansion of domestic market), the transfer of overseas industrial chain to China and policy support.

(1) The application for new drugs is accelerating, and the demand for innovative drug research and development is hot. The number of clinical applications for domestic new drugs has increased rapidly. In 2020, there were 448 new clinical applications for innovative drugs/kloc-0, an increase of over 70% year-on-year. These applications are expected to enter the clinical stage in the future and be transformed into medical outsourcing orders.

(2) The overseas industrial chain is transferred to China. Under the influence of the epidemic, the trend of industrial chain transfer to China continues. Innovative pharmaceutical companies are more willing to reduce costs and increase efficiency through R&D outsourcing under the pressure of R&D investment; Moreover, foreign-funded pharmaceutical outsourcing enterprises are affected by overseas epidemics, which helps domestic enterprises to increase their share.

(3) The state encourages the development of pharmaceutical outsourcing industry at the policy level. The Notice on Organizing the Implementation of Biomedical Contract R&D and the Construction of Production Service Platform issued on 20 18 proposes to support a number of high-level and international comprehensive pharmaceutical outsourcing service platforms. Priority review of innovative drugs (accelerated listing process), trial implementation of MAH system (separation of drug listing license and production license), and medical insurance fee control (centralized procurement of generic drugs) have all increased the demand for drug outsourcing.